Back

Potent P2Y12 inhibition with ticagrelor over clopidogrel in complex PCI: a systematic review and meta-analysis of clinical outcomes

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Optimising outcomes in percutaneous coronary intervention: risk assessment, pharmacotherapy, and clinical insights Adjunctive Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Andre Dos Santos Cleto

HAOC - Hospital Augusto de Oliveira Camargo, Indaiatuba (Brazil)

5 More presentations in this session

Presentation thumbnail
CKD severity and high bleeding risk in patients undergoing PCI: stage-specific validation of modified ARC-HBR criteria
Doctor F. Di Muro (Salerno, IT)
Abstract
Presentation thumbnail
Association of ANGPTL3, ANGPTL4, and DOCK7 polymorphisms with lipid traits and long-term clinical outcomes in patients undergoing PCI
Doctor Y. Song (Beijing, CN)
Abstract
Presentation thumbnail
Early bleeding risk prediction with the PRECISE-HBR score in PCI patients treated with cangrelor: the ICARUS registry
Doctor V. De Sio (Caserta, IT)
Abstract
Presentation thumbnail
Perfusion balloon prolonged inflation in lipid-rich coronary lesions and slow flow/no-reflow: NIRS-IVUS insights
Doctor S. Izumoto (Miyazaki, JP)
Abstract
Presentation thumbnail
Women demonstrate better one-year survival than men after microaxial pump-supported high-risk PCI
Associate Professor J. Sacha (Opole, PL)
Abstract

Access the full session

Session thumbnail
Optimising outcomes in percutaneous coronary intervention: risk assessment, pharmacotherapy, and clinical insights

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Real world outcomes for clopidogrel versus ticagrelor treated patients with acute coronary syndrome: a systematic literature review and meta-analysis
2 September 2019
thumbnail
Congress Presentation
Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study
26 August 2023
thumbnail
Congress Presentation
Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis
1 September 2020
thumbnail
Congress Presentation
STEMI antiplatelet pretreatment strategy - national multicenter registry experience
9 March 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources